Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 336

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 16I
Chunk 336
---
 premium increases from exercise of subscription rights                                           —             1,770             6,695         23  
  Net cash flows used in financing activities                                                                               ( 4,924)          ( 5,001)          ( 1,487)             
  Decrease in cash and cash equivalents                                                       €                           ( 104,353)        ( 339,785)      ( 1,747,545)             
  Cash and cash equivalents at beginning of year                                              €                              166,810           508,117         2,233,368         22  
  Decrease in cash and cash equivalents                                                                                   ( 104,353)        ( 339,785)      ( 1,747,545)             
  Effect of exchange rate differences on cash and cash equivalents                                                             1,782          ( 1,522)            22,293             
  Cash and cash equivalents at end of year                                                    €                               64,239           166,810           508,117         22  

The accompanying notes form an integral part of these financial statements.

F-10

Table of Contents

Notes to Consolidated Financial Statements
1. General information
Galapagos NV is a limited liability company incorporated in Belgium and has its registered office at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium. In the notes to the consolidated financial statements, references to “we,” “us,” “the group” or “ Galapagos” include Galapagos NV together with its subsidiaries. We refer to note 34 for a list of consolidated companies.
We are a global biotechnology company with operations in Europe and the US dedicated to developing medicines focusing on oncology and immunology.
The components of the result presented in the financial statements include the results of the companies mentioned in note 34 Consolidated companies as of December 31, 2024.
Our operations had704employees on December 31, 2024 (as compared to1,123employees on December 31, 2023, of which646employees working in our continuing operations) mainly working in our operating facilities in Mechelen (the Belgian headquarters), the Netherlands, France, Switzerland, and the United States.
On January 31, 2024 we announced that we successfully completed the transfer of the Jyseleca® business to Alfasigma, including the European and UK Marketing Authorizations, the commercial, medical and development activities for Jyseleca® and approximately400